KALA BIO
KALA
112 hedge funds and large institutions have $252M invested in KALA BIO in 2020 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 18 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
7% more funds holding
Funds holding: 105 → 112 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.49% less ownership
Funds ownership: 67.85% → 66.36% (-1.5%)
11% less call options, than puts
Call options by funds: $3.29M | Put options by funds: $3.7M
12% less capital invested
Capital invested by funds: $285M → $252M (-$33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.46M |
| 2 |
Millennium Management
New York
|
+$4.05M |
| 3 |
Two Sigma Investments
New York
|
+$3.52M |
| 4 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$2.78M |
| 5 |
Two Sigma Advisers
New York
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.9M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.75M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.47M |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$1.15M |
| 5 |
Goldman Sachs
New York
|
-$1.05M |
KALA Hedge Fund Activity: Q4 2020 in Review
112 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q4 2020, worth a combined $252M — down 12% from $285M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KALA positions and 18 closed out — a net gain of 7 holders — while 36 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $4.46M. The largest seller was Fidelity Investments, cutting an estimated $20.9M.
- 112 institutional investors held KALA BIO (KALA) as of Q4 2020, up from 105 in Q3 2020.
- Funds reported $252M of KALA BIO stock for Q4 2020, down 12% quarter-over-quarter.
- 25 funds opened new KALA BIO positions in Q4 2020 and 18 closed out, a net change of +7 holders.
- The largest KALA BIO buyer in Q4 2020 was BlackRock, an estimated $4.46M added.
- The largest KALA BIO seller in Q4 2020 was Fidelity Investments, an estimated $20.9M sold.
Based on aggregated 13F filings for Q4 2020.